e-learning
resources
Madrid 2019
Tuesday, 01.10.2019
CCC Interstitial lung diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Rituximab therapy in a patient with steroid-refractory bird fancier's lung
E. Ceci Bonello (Naxxar, Malta)
Source:
International Congress 2019 – CCC Interstitial lung diseases
Session:
CCC Interstitial lung diseases
Session type:
Challenging clinical cases
Number:
3503
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Ceci Bonello (Naxxar, Malta). Rituximab therapy in a patient with steroid-refractory bird fancier's lung. International Congress 2019 – CCC Interstitial lung diseases
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
Granulomatous lung disease in lymphoma patient after rituximab treatment
Source: Virtual Congress 2020 – Interstitial lung diseases
Year: 2020
Rituximab in the treatment of refractory pulmonary sarcoidosis
Source: Eur Respir J 2014; 43: 1525-1528
Year: 2014
Cyclophosphamide in steroid-refractory hypersensitivity pneumonitis and non-classifiable interstitial lung disease
Source: International Congress 2017 – Novel and old entities
Year: 2017
Rituximab therapy for interstitial lung disease in patients with antisynthetase syndrome
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013
Wegener's granulomatosis after Montelukast in patient not receiving systemic steroid treatment
Source: Eur Respir J 2002; 20: Suppl. 38, 65s
Year: 2002
Rituximab for the treatment of chronic hypersensitivity pneumonitis
Source: International Congress 2015 – Interstitial lung diseases I
Year: 2015
Hypersensitivity pneumonitis secondary to lovebirds: a new cause of bird fancier's disease
Source: Eur Respir J 2008; 32: 517-521
Year: 2008
Efficacy of switching from cyclosporine A to tacrolimus in patients with refractory CTD-ILD
Source: International Congress 2016 – Connective tissue disorders
Year: 2016
Pulmonary tuberculosis in hodgkin's disease after high dose chemotherapy
Source: Annual Congress 2003 - Clinical aspects of tuberculosis
Year: 2003
Infliximab for treating sarcoidosis, portuguese experience
Source: Annual Congress 2009 - Sarcoidosis in review
Year: 2009
Tacrolimus for antisynthetase syndrome with interstitial lung disease?
Source: Eur Respir J 2008; 32: 244-245
Year: 2008
Severe fibrotic lung disease – How much therapy is too much therapy?
Source: Annual Congress 2008 - Clinical Grand Round - an interactive session
Year: 2008
Pneumococcal vaccination in interstitial lung disease patients receiving systemic immunosuppressive treatment
Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis
Year: 2017
Infliximab treatment in patients with interstitial lung disease and rheumatoid arthritis
Source: Eur Respir J 2002; 20: Suppl. 38, 587s
Year: 2002
Infliximab: An effective rescue therapy in refractory extra-pulmonary sarcoidosis
Source: Annual Congress 2013 –Sarcoidosis and other granulomatosis
Year: 2013
Infliximab therapy in interstitial lung disease associated with rheumatoid arthritis
Source: Annual Congress 2004 - Fibrosing lung diseases
Year: 2004
Rituximab improves interstitial lung disease in rheumatoid arthritis patients
Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment
Year: 2017
Effect of infliximab on lung function and well-being in patients with refractory sarcoidosis
Source: Annual Congress 2011 - Different profiles of sarcoidosis and other granulomatous disorders
Year: 2011
Rituximab treatment of a case of anti-syntetase syndrome with severe interstitial lung disease and acute respiratory failure
Source: Annual Congress 2010 - Clinical issues in diffuse parenchymal lung disease
Year: 2010
Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept